Bone Therapeutics SA
BOTHE.BR News Today: Stay Updated with the Latest Bone Therapeutics SA News in Real Time
Find BOTHE.BR news now at Meyka AI. Stay informed with the latest Bone Therapeutics SA stocks updates, including price news, market analysis, and expert insights.
ITRM Iterum Therapeutics plc NASDAQ Q4 2025 results 03 Apr 2026: Earnings drivers and outlook
ITRM stock closed at $0.03 on 03 Apr 2026 after Q4 2025 results. Read Meyka AI earnings spotlight and short-term outlook for ITRM stock
BTIG Maintains ALDX (Aldeyra Therapeutics) at Buy on Mar 17, 2026
BTIG maintains Buy on ALDX; ALDX analyst rating reviewed after Mar 17, 2026 note
Pre-Market: MMTX.SW stock rises 8.02% on SIX, watch volume for follow-through
MMTX.SW stock climbs 8.02% pre-market on SIX to CHF 0.35; technical oversold signals and Meyka AI forecast highlight near-term upside
Jefferies Maintains Buy for CTMX (CytomX Therapeutics) March 18, 2026
Jefferies maintained Buy on CTMX March 18, 2026. Read CTMX analyst rating, $16 PT, and Meyka AI grade B+
Jefferies Maintains Buy on Protagonist Therapeutics (PTGX) PT $121 Mar 2026
PTGX analyst rating update: Jefferies, Johnson Rice maintain Buy; PT $121 and royalty model cited
CHM.AX gains 100% pre-market on ASX: clinical catalysts and liquidity signal
Pre-market: CHM.AX stock jumps 100% to A$0.002 on ASX. We analyse drivers, valuation and Meyka AI forecast
CHF2.885 intraday (SIX): RLF.SW Relief Therapeutics may test CHF3.20 31 Mar 2026
RLF.SW stock intraday: CHF2.885, oversold bounce setup on SIX. Meyka AI forecast and technical outlook for Relief Therapeutics
March 31: JAXA Astronaut Satoshi Furukawa Retires, Spotlights Space MedTech
Satoshi Furukawa JAXA retirement on March 31 spotlights space medicine Japan. He becomes Kyorin University professor after 366 days in space, creating new medtech and research links investors should,
ITRM Iterum Therapeutics plc NASDAQ -66% intraday 30 Mar 2026: heavy volume
ITRM stock down 66% intraday on NASDAQ 30 Mar 2026 with huge volume; short-term outlook and Meyka AI forecast compare risks and upside